Company intelligence / Profile preview

mAbxience Research S.L.

Madrid, Spain

Ownership: Private
Employees: ~1000
Development stage: Other

Overview

mAbxience has launched two biosimilars (rituximab and bevacizumab) worldwide and has several late-stage biosimilar and innovative biopharmaceutical programs, with first approvals in major regions starting in 2014 for rituximab and 2016 for bevacizumab[6][5]. The pipeline includes programs in oncology, hematology, bone disease, and autoimmune disorders, with products in Phase 3 and NDA/BLA stages[5][6].

Therapeutic areas: OncologyEndocrinologyRheumatologyOther
Modalities: Monoclonal antibodyBiosimilarFusion protein
Industry: Biotech

Partnerships

30+ global/regional partnersAmneal (denosumab biosimilar program)numerous B2B and regulated market alliances

Beyond the preview

Go deeper on mAbxience Research S.L..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mAbxience Research S.L..

Explore the full profile